Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben George

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
The Oncologist|February 25, 2026
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella StudyGulam A Manji, Vincent Chung, Do-Youn Oh, et al.
JAMA Oncology|October 11, 2019
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical TrialDavid H Ilson, Josep Tabernero, Aliaksandr Prokharau, et al.
Frontiers in Oncology|May 1, 2020
Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic CancerDavid Wittmann, William A Hall, Kathleen K Christians, et al.
Physics in Medicine and Biology|February 25, 2021
IPEM Topical Report: an international IPEM survey of MRI use for external beam radiotherapy treatment planningRichard Speight, Marcus Tyyger, Maria A Schmidt, et al.
Practical Radiation Oncology|August 25, 2024
Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment VolumesSara E Beltran Ponce, Christina J Small, Talha Ahmad, et al.
Cancer Medicine|December 23, 2023
Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapySaryleine de Ortiz de Choudens, Alexis Visotcky, Anjishnu Banerjee, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Spatial Conformation of Pancreatic Cancer Is Associated with Disease Recurrence after Curative-Intent Total Neoadjuvant TherapyLuis H Cisneros, Merih D Toruner, Zafar Siddiqui, et al.
Cancers|February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
The Oncologist|February 25, 2026
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella StudyGulam A Manji, Vincent Chung, Do-Youn Oh, et al.
JAMA Oncology|October 11, 2019
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical TrialDavid H Ilson, Josep Tabernero, Aliaksandr Prokharau, et al.
Frontiers in Oncology|May 1, 2020
Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic CancerDavid Wittmann, William A Hall, Kathleen K Christians, et al.
Physics in Medicine and Biology|February 25, 2021
IPEM Topical Report: an international IPEM survey of MRI use for external beam radiotherapy treatment planningRichard Speight, Marcus Tyyger, Maria A Schmidt, et al.
Practical Radiation Oncology|August 25, 2024
Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment VolumesSara E Beltran Ponce, Christina J Small, Talha Ahmad, et al.
Cancer Medicine|December 23, 2023
Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapySaryleine de Ortiz de Choudens, Alexis Visotcky, Anjishnu Banerjee, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Spatial Conformation of Pancreatic Cancer Is Associated with Disease Recurrence after Curative-Intent Total Neoadjuvant TherapyLuis H Cisneros, Merih D Toruner, Zafar Siddiqui, et al.
Cancers|February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Pageof 13